Feasibility of Implanting 50-60 mm-Tapered Drug Eluting Stents in Chronic Total Occlusions

Cardiovasc Revasc Med. 2019 Dec;20(12):1117-1122. doi: 10.1016/j.carrev.2019.02.020. Epub 2019 Feb 20.

Abstract

Background: Percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) usually involves multiple overlapping stents implantation to cover long coronary segments. A higher rate of restenosis has been described with stent overlapping. Recently, new long tapered stents emerged as a potential tool for treating long coronary lesions. Feasibility of using these new devices for the CTO PCI has not been described. The aim of this work was to describe our initial experience with 50 and 60 mm-long tapered sirolimus-eluting stents (SES) in CTO PCI.

Methods: We included 54 consecutive patients who underwent a CTO PCI and in whom an attempt to implant a 50 or 60 mm-long tapered SES was performed. Baseline clinical, angiographic, and procedural characteristics were recorded.

Results: The median (IQR) age was 64 (58-73) years, and 45 (83.3%) patients were male. The tapered SES 50 and 60 mm-long was successfully implanted in 51 (94.4%) patients. In three patients, a 60 mm-long stent could not be implanted, and two or three overlapped shorter drug-eluting stents were deployed instead. An average of 1.4 ± 0.6 stents per patient was implanted. A single stent was deployed in 32 (59.3%) patients. During a median follow-up of 330 (149-551) days, repeat PCI in the target vessel was performed in two patients.

Conclusions: The use of the new BioMime Morph™ tapered SES for the treatment of CTO appears to be feasible in a high proportion of procedures. Further studies confirming the feasibility of this approach and its potential clinical advantages are needed.

Keywords: Chronic total occlusions; Feasibility; Long coronary stents; Sirolimus stents; Tapered stents.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Cardiovascular Agents / administration & dosage
  • Chronic Disease
  • Coronary Occlusion / diagnostic imaging
  • Coronary Occlusion / physiopathology
  • Coronary Occlusion / therapy*
  • Coronary Restenosis / etiology
  • Coronary Restenosis / physiopathology
  • Drug-Eluting Stents*
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention / adverse effects
  • Percutaneous Coronary Intervention / instrumentation*
  • Prosthesis Design
  • Retrospective Studies
  • Sirolimus / administration & dosage
  • Time Factors
  • Treatment Outcome
  • Vascular Patency

Substances

  • Cardiovascular Agents
  • Sirolimus